Captrust Financial Advisors Has $110,000 Position in MiMedx Group, Inc. (NASDAQ:MDXG)

Captrust Financial Advisors lowered its holdings in MiMedx Group, Inc. (NASDAQ:MDXG) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,471 shares of the company’s stock after selling 2,087 shares during the quarter. Captrust Financial Advisors’ holdings in MiMedx Group were worth $110,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in MDXG. BNP Paribas Financial Markets bought a new stake in shares of MiMedx Group during the fourth quarter valued at approximately $450,000. Ameriprise Financial Inc. acquired a new position in MiMedx Group in the fourth quarter valued at approximately $115,000. Jane Street Group LLC raised its holdings in MiMedx Group by 26.2% in the fourth quarter. Jane Street Group LLC now owns 385,594 shares of the company’s stock worth $3,709,000 after purchasing an additional 79,942 shares during the period. Connors Investor Services Inc. raised its holdings in MiMedx Group by 23.4% in the fourth quarter. Connors Investor Services Inc. now owns 24,676 shares of the company’s stock worth $237,000 after purchasing an additional 4,676 shares during the period. Finally, First Light Asset Management LLC acquired a new stake in MiMedx Group in the fourth quarter worth $32,168,000. 79.15% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Joseph H. Capper acquired 200,000 shares of MiMedx Group stock in a transaction dated Friday, May 2nd. The stock was bought at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at $3,357,220.20. This represents a 60.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now directly owns 310,836 shares of the company’s stock, valued at approximately $2,452,496.04. This trade represents a 1.30% decrease in their position. The disclosure for this sale can be found here. Insiders sold 144,018 shares of company stock valued at $1,130,312 over the last quarter. 1.70% of the stock is owned by company insiders.

MiMedx Group Trading Down 2.6%

MDXG stock opened at $6.72 on Friday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The company’s 50-day simple moving average is $7.11 and its 200 day simple moving average is $8.17. MiMedx Group, Inc. has a 52 week low of $5.47 and a 52 week high of $10.14. The company has a market capitalization of $992.56 million, a PE ratio of 12.22 and a beta of 1.85.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $88.21 million during the quarter, compared to analysts’ expectations of $86.32 million. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. As a group, sell-side analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have commented on MDXG. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th. Wall Street Zen downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, May 9th.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.